P. Fustier

发表

Identification of polymorphisms in the human 11beta‐hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity

Arya M. Sharma, F. Frey, B. Frey, 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines.

Y. Bignon, P. Fustier, L. Le Corre, 2004, Clinica chimica acta; international journal of clinical chemistry.

Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines

Y. Bignon, P. Fustier, D. BERNARD-GALLON, 2002, British Journal of Nutrition.

Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).

C. Mamot, R. Cathomas, P. Fustier, 2013, Clinical lung cancer.

Presence of BRCA1 and BRCA2 proteins in human milk fat globules after delivery.

Y. Bignon, P. Fustier, L. Le Corre, 2002, Biochimica et biophysica acta.

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

J. Gribben, J. Leonard, I. Flinn, 2018, Blood.

Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines

Y. Bignon, P. Fustier, L. Le Corre, 2003, British Journal of Cancer.

Insulin, CCAAT/Enhancer-Binding Proteins and Lactate Regulate the Human 11β-Hydroxysteroid Dehydrogenase Type 2 Gene Expression in Colon Cancer Cell Lines

F. Frey, B. Frey, Rasoul Alikhani-Koupaei, 2014, PloS one.

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

L. Staudt, R. Gascoyne, G. Salles, 2017, Clinical Cancer Research.

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

J. Gribben, J. Leonard, I. Flinn, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells.

I. G. Fantus, J. Ingelfinger, P. Hamet, 2004, The Journal of endocrinology.

High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells.

I. G. Fantus, J. Ingelfinger, P. Hamet, 2003, Endocrinology.

AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS

M. Czuczman, I. Flinn, K. Izutsu, 2019, Hematological Oncology.

Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma

K. Izutsu, K. Tobinai, P. Fustier, 2019, International Journal of Hematology.

Extracellular ATP determines 11beta-hydroxysteroid dehydrogenase type 2 activity via purinergic receptors.

F. Frey, B. Frey, P. Fustier, 2005, Journal of the American Society of Nephrology : JASN.